

Migration Inconsistencies in Electronic Quality of Life (QOL) Instruments in Clinical Trials



Lindsay Hughes¹, Margalida Frau², Elinor Rees³

¹IQVIA New York, US; ²IQVIA Madrid, Spain; ³IQVIA Reading, UK

Background

- Ensuring scientific integrity in clinical research requires that trials are designed and conducted so participants receive information and assessments in their native language. This is especially important for achieving representation in clinical trials, but also for maintaining the integrity of the data collected – since language and cultural context can influence how participants interpret and respond to assessments

Introduction

- A standardized migration^{1,2} process is used to convert validated paper-based Clinical Outcome Assessments (COAs) into electronic formats while preserving their original linguistic and conceptual integrity (i.e., maintaining the same wording in the electronic formats and making slight adjustments where necessary to account for electronic administration). This involves collaboration with eCOA providers, language experts, and native speakers. The result is a set of electronic files used to generate screenshots for review and validation. Depending on the instrument's complexity, this process may take several weeks
- Despite these rigorous procedures, there is an industry-wide challenge in the eCOA migration process. Inconsistencies across languages and countries are common and can compromise data quality, reduce credibility, and discourage participant engagement
- This research focuses on migration-related challenges in less common languages compared to those frequently used in Quality of Life (QOL) instruments in clinical trials

Methods

Trials were selected based on two criteria: the availability of COAs measuring QOL and the presence of both common and less common languages

Common languages	Less common languages
Those frequently used in clinical research settings (Spanish, German, Japanese, French)	Those spoken in countries where eCOA use is limited or where the languages are considered unofficial, minority or primarily associated with immigrant populations (Haitian Creole, Vietnamese, Cebuano, Armenian, Farsi)

Qualified linguists under the oversight of IQVIA's Translation Services (ITS) team compared paper- and migrated version of COAs to identify migration-related challenges and translation issues across multi-sponsor studies covering various indications and therapeutic areas. PCS Scientific team then reviewed these findings and categorized the issues to highlight patterns and support further investigation

Results

- The total number of issues was similar across common and less common languages (Table 1). However, the mean number of issues per trial was higher in less common languages than in common ones (42 vs 8, respectively; Figure 1)
- The inconsistencies identified were distributed across the following categories (Examples can be observed in Figure 2):
 - Copyright issues
 - Electronic wording
 - Emphasis (e.g., bolded text)
 - Grammatical error
 - Punctuation
 - Screen format
 - Translation mismatch
 - Untranslated content

	Number of issues
Common languages	222
Spanish	35
German	102
Japanese	9
French	76
Less common languages	209
Haitian Creole	62
Vietnamese	42
Cebuano	1
Armenian	22
Farsi	82




Table 1. Number of issues per language and group of languages




Figure 2. Illustrative examples of the different types of issues identified

This figure shows illustrative examples due to copyright restrictions. Original content was translated and adapted for dissemination and does not exactly reflect the original wording

Conclusions

- Language and cultural diversity are essential for inclusive clinical trials and reliable outcomes. Minor inconsistencies – especially in language – can affect patient experience and introduce bias, risking data integrity
- To prevent this, it is essential to ensure that the full migration process is also carried out by trained native-speaking linguists who have been provided with clear instructions. Automation is strongly encouraged to reduce manual intervention and ensure adherence to legacy text. In regions with limited eCOA experience, enhanced automation and extra review cycles are necessary to meet industry standards

References

¹Shalhoub, H., Turner, M., Bradley-Gilbride, A., Eremenco, S., Muehlan, H., Parks-Vernizzi, E., Arnold, B., Kulic, D., Anfray, C., Chaplin, J. E., & Repo, J. P. (2025). Principles of good practice for translation of electronic clinical outcome assessments. *Journal of Patient-Reported Outcomes*, 9(26).

²Mowlem, F. D., Elash, C. A., Dumais, K. M., Haenel, E., O'Donohoe, P., Olt, J., Kalpadakis-Smith, A. V., James, B., Balestrieri, G., Becker, K., Newara, M. C., & Kern, S. (2024). Best Practices for the Electronic Implementation and Migration of Patient-Reported Outcome Measures. *Value in Health*, 27(1), 79–94.